Get started
Merck & Co., Inc.Merck & Co., Inc.Merck & Co., Inc.

Merck & Co., Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

MRKCL chart


Full chart

Key facts today


Merck & Co. generates approximately 20% of its revenue from its vaccine business, with the HPV vaccine Gardasil recognized as the company's second-best-selling product.
Merck & Co. has scrapped plans for a £1 billion research center in London, citing a tough UK business climate affecting pharmaceutical investments due to drug pricing and competitiveness concerns.
Analyze the impactAnalyze the impact

MRKCL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪205.49 T‬ CLP
Dividend yield (indicated)
3.81%
Price to earnings Ratio (TTM)
12
Basic EPS (TTM)
6,084 CLP
Net income (FY)
‪17.08 T‬ CLP
Revenue (FY)
‪63.85 T‬ CLP
Shares float
‪2.50 B‬
Beta (1Y)
0.46

Employees


Employees (FY)
‪75 K‬
Change (1Y)
‪+3 K‬ +4.17%
Revenue / Employee (1Y)
‪851.27 M‬ CLP
Net income / Employee (1Y)
‪227.77 M‬ CLP

About Merck & Company, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Robert M. Davis
Website
merck.com
Headquarters
Rahway
Founded
1891
ISIN
US58933Y1055
FIGI
BBG00YFSTJK2
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Check out other big names from the same industry as MRKCL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MRKCL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

MRKCL highest yielding bonds


MRK3671638
Schering-Plough Corporation 6.55% 15-SEP-2037
Yield to maturity
—
Maturity date
Sep 15, 2037
MRK6166087
Merck & Co., Inc. 5.7% 15-SEP-2055
Yield to maturity
—
Maturity date
Sep 15, 2055
MRK3900816
Merck & Co., Inc. 3.6% 15-SEP-2042
Yield to maturity
—
Maturity date
Sep 15, 2042
MRK6165795
Merck & Co., Inc. FRN 15-SEP-2027
Yield to maturity
—
Maturity date
Sep 15, 2027
MRK.GF
Merck & Co., Inc. 5.76% 03-MAY-2037
Yield to maturity
—
Maturity date
May 3, 2037
MRK5002722
Merck & Co., Inc. 1.45% 24-JUN-2030
Yield to maturity
—
Maturity date
Jun 24, 2030
MRK.GA
Merck & Co., Inc. 6.3% 01-JAN-2026
Yield to maturity
—
Maturity date
Jan 1, 2026
MRK5002693
Merck & Co., Inc. 2.45% 24-JUN-2050
Yield to maturity
—
Maturity date
Jun 24, 2050
MRK6165794
Merck & Co., Inc. 3.85% 15-SEP-2027
Yield to maturity
—
Maturity date
Sep 15, 2027
MRK4806277
Merck & Co., Inc. 3.4% 07-MAR-2029
Yield to maturity
—
Maturity date
Mar 7, 2029
MRK5584756
Merck & Co., Inc. 5.15% 17-MAY-2063
Yield to maturity
—
Maturity date
May 17, 2063

See all MRKCL bonds 

Sparks


Curated watchlists where MRKCL is featured.

See all sparks 

Frequently Asked Questions


The current price of MRKCL is 76,219 CLP — it hasn't changed in the past 24 hours. Watch Merck & Co., Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BCS exchange Merck & Co., Inc. stocks are traded under the ticker MRKCL.
MRKCL stock has fallen by −2.20% compared to the previous week, the month change is a −2.20% fall, over the last year Merck & Co., Inc. has showed a −32.79% decrease.
We've gathered analysts' opinions on Merck & Co., Inc. future price: according to them, MRKCL price has a max estimate of 136,760.43 CLP and a min estimate of 79,534.43 CLP. Watch MRKCL chart and read a more detailed Merck & Co., Inc. stock forecast: see what analysts think of Merck & Co., Inc. and suggest that you do with its stocks.
MRKCL reached its all-time high on Mar 28, 2024 with the price of 130,550 CLP, and its all-time low was 53,962 CLP and was reached on May 4, 2021. View more price dynamics on MRKCL chart.
See other stocks reaching their highest and lowest prices.
MRKCL stock is 7.63% volatile and has beta coefficient of 0.46. Track Merck & Co., Inc. stock price on the chart and check out the list of the most volatile stocks — is Merck & Co., Inc. there?
Today Merck & Co., Inc. has the market capitalization of ‪205.49 T‬, it has decreased by −0.82% over the last week.
Yes, you can track Merck & Co., Inc. financials in yearly and quarterly reports right on TradingView.
Merck & Co., Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
MRKCL earnings for the last quarter are ‪1.99 K‬ CLP per share, whereas the estimation was ‪1.90 K‬ CLP resulting in a 4.77% surprise. The estimated earnings for the next quarter are ‪2.29 K‬ CLP per share. See more details about Merck & Co., Inc. earnings.
Merck & Co., Inc. revenue for the last quarter amounts to ‪14.79 T‬ CLP, despite the estimated figure of ‪14.84 T‬ CLP. In the next quarter, revenue is expected to reach ‪16.45 T‬ CLP.
MRKCL net income for the last quarter is ‪4.14 T‬ CLP, while the quarter before that showed ‪4.84 T‬ CLP of net income which accounts for −14.47% change. Track more Merck & Co., Inc. financial stats to get the full picture.
Yes, MRKCL dividends are paid quarterly. The last dividend per share was 761.28 CLP. As of today, Dividend Yield (TTM)% is 3.76%. Tracking Merck & Co., Inc. dividends might help you take more informed decisions.
Merck & Co., Inc. dividend yield was 3.14% in 2024, and payout ratio reached 46.32%. The year before the numbers were 2.72% and ‪2.07 K‬% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 13, 2025, the company has ‪75 K‬ employees. See our rating of the largest employees — is Merck & Co., Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Merck & Co., Inc. EBITDA is ‪25.04 T‬ CLP, and current EBITDA margin is 39.30%. See more stats in Merck & Co., Inc. financial statements.
Like other stocks, MRKCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Merck & Co., Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Merck & Co., Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Merck & Co., Inc. stock shows the sell signal. See more of Merck & Co., Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.